Markets:

Overview

News

Currencies

International

Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

46.58 +0.19 (+0.41%)

Streaming Delayed Price Updated: 3:36 PM EST, Dec 2, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Veracyte to Participate in the Stephens Annual Investment Conference

November 02, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development

October 27, 2023

From Veracyte, Inc.

Via Business Wire

7 Undervalued Stocks That Analysts Love Right Now ↗

October 26, 2023

With many investors concerned about what may lie ahead in the market, these potentially de-risked undervalued stocks may be ideal.

Via InvestorPlace

The Latest Analyst Ratings for Veracyte ↗

October 20, 2023

Via Benzinga

Here's Why This Little-Known Growth Stock Is a Buy ↗

May 22, 2023

Analysts think this genomic test maker could have major upside in the next year.

Via The Motley Fool

Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023

October 17, 2023

From Veracyte, Inc.

Via Business Wire

New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease

October 12, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Stock Is Volatile After-Hours - Here's Why ↗

October 04, 2023

Veracyte, Inc. (NASDAQ: VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value of the Decipher Prostate Genomic Classifier...

Via Benzinga

New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier

October 04, 2023

From Veracyte, Inc.

Via Business Wire

New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

September 28, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023

September 28, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

September 27, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting

September 21, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests

September 07, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies

September 06, 2023

From Veracyte, Inc.

Via Business Wire

Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? ↗

September 02, 2023

The genetic test maker is rapidly increasing test volumes.

Via The Motley Fool

Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

August 29, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

August 22, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego

August 15, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Second Quarter 2023 Financial Results

August 08, 2023

From Veracyte, Inc.

Via Business Wire

Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment

August 01, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023

July 19, 2023

From Veracyte, Inc.

Via Business Wire

Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom ↗

July 08, 2023

AI is changing the face of biotechnology and drug discovery. Don't miss out on the next big boom in biotech, here are 3 stocks to consider.

Via InvestorPlace

New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

June 20, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023

June 12, 2023

From Veracyte, Inc.

Via Business Wire

Market Mixes It Up With A Broad Rally ↗

June 05, 2023

Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive.

Via Talk Markets

Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June

May 31, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END

Via FinancialNewsMedia

New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer

May 25, 2023

From Veracyte, Inc.

Via Business Wire

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

May 24, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in Upcoming Investor Conferences

May 23, 2023

From Veracyte, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.